OTHER GROUP COMPANIES
market

Orchid Pharma receives EIR from US FDA for Kancheepuram facility

The facility was inspected by USFDA in the month of August 2015.

April 11, 2016 11:29 IST | India Infoline News Service
Orchid Pharma Ltd has announced that it has received the Establishment inspection report (EIR) from USFDA based on the successful inspection closure for the API manufacturing facility located at Alathur, Kancheepuram District, India. The facility was inspected by USFDA in the month of August 2015.

Orchid Pharma Ltd is currently trading at Rs. 39.95, up by Rs. 1.2 or 3.1% from its previous closing of Rs. 38.75 on the BSE.
The scrip opened at Rs. 39.45 and has touched a high and low of Rs. 40.7 and Rs. 39.45 respectively. So far 333268(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 344.74 crore.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 75.3 on 06-Aug-2015 and a 52 week low of Rs. 32.6 on 29-Feb-2016. Last one week high and low of the scrip stood at Rs. 40.5 and Rs. 37.35 respectively.
The promoters holding in the company stood at 38.41 % while Institutions and Non-Institutions held 5.39 % and 52.41 % respectively.
The stock is currently trading above its 200 DMA.

OPEN A DEMAT ACCOUNT & Get FREE Benefits worth 10,000

OPEN A DEMAT ACCOUNT & Get
FREE Benefits worth 10,000

STOCK VIEW

PRESTIGE (NSE)

The average score for Prestige Estates Projects Limited stands at 4 against 6, three months back.

Prestige Estates Projects Limited is engaged in the business of real estate development. The Company’s principal products/services include Development and construction

FEATURED ARTICLE

BLOGS

Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity